Table 1.
Θ | Tvθ | CV (%) | ω |
---|---|---|---|
Vc (L/kg) | 3.68 | 23.47 | 0.095 |
Vp (L/kg) | 5.04 | 41.47 | 0.009 |
VSS (L/kg) | 8.72 | 28.75 | / |
Cl (L/kg·h) | 16.39 | 12.67 | 0.126 |
Q (L/kg·h) | 8.34 | 41.37 | 0.391 |
AUC0-inf (ng·h/mL) | 76.26 | 12.67 | / |
C0 (ng/mL) | 339.59 | 23.47 | / |
Ke (1/h) | 4.45 | 26.27 | / |
MRT (h) | 0.53 | 31.56 | / |
T1/2α (h) | 0.09 | 33.26 | / |
T1/2β (h) | 0.69 | 40.41 | / |
Θ: fixed effect parameter; Tvθ: population typical value of the fixed effect parameter; CV: coefficient of variation; ω: variance of the interindividual variability (only for fixed parameters). Addition of the covariate experimental diet (control versus FBs-contaminated) did not significantly improve the –2 log likelihood (–2LL) of any of the fixed effect parameters, and was therefore not retained in the final model. Vc: volume of distribution of the central compartment; Vp: volume of distribution of the peripheral compartment; Vss: volume of distribution at steady state; Cl: total body clearance; Q: intercompartmental flow, AUC0-inf: area under the plasma concentration–time curve from time 0 to infinity; C0: plasma concentration at time 0 following IV administration; Ke: elimination rate constant; MRT: mean residence time; T1/2α: distribution half-life, and T1/2β: elimination half-life.